Clinical Imaging and Case Reports (ISSN 2770-9205)

"In contrast to other neuronal activities recorded from the other five brain areas, the Serotonergic Signaling and the Dorsal Raphe (DR) Neurons in Adolescent Rats are the Most Engaged in Response to Acute and Chronic Methylphenidate."

Dafny N

Corresponding author

Dafny N,Department of Neurobiology and Anatomy, UT Houston McGovern Medical School, USA.

Received Date: Jan 12 2023
Accepted Date: Jan 13 2023
Published Date: Feb 15 2023

Abstract

A CNS stimulant called methylphenidate (MPD) is well-known for treating behavioural disorders. Its rising popularity among "normal" people for cognitive enhancement and leisure has created a significant public health issue. According to this study, acute MPD exposure mostly results in increases in neuronal and behavioural activity in dose response characteristics. Chronic MPD exposure, as opposed to acute MPD (0.6, 2.5, or 10.0 mg/kg), causes electrophysiological sensitization and behavioural intolerance in some animals while eliciting tolerance in others. The majority of the neurons recorded from animals displaying behavioural sensitization responded to chronic MPD by increasing their firing rate compared to the initial MPD exposure when evaluations of neuronal recordings were based on the animals' behavioural responses to chronic MPD.

Moreover, most of the Neurons recorded from animals displaying behavioural tolerance decreased in firing rate after chronic MPD treatment compared to before the MPD exposure. The VTA, LC, DR, NAc, PFC, and CN all responded to MPD significantly differently, indicating that each of the aforementioned brain areas plays a unique function in the reaction to MPD. The most sensitive neurons to MPD were those in the DR. The study shows that in order to accurately determine the function of each neuron in reaction to a drug, it is crucial to measure neuronal activity responses to psychostimulants based on the animal's behavioural responses from multiple brain areas concurrently. MPD causes symptoms that are typical of diseases that involve substance misuse.

Introduction

A psychostimulant called methylphenidate (MPD) is used to treat behavioural conditions such Attention Deficit Hyperactivity Disorder (ADHD) [1-3]. Abuse and use of MPD have skyrocketed in recently by common children and adults for cognitive improvement and entertainment goals [4–8]. By competing with DA, NE, and 5HT transporters for re-uptake from the synaptic cleft into the presynaptic terminals, MPD modifies monoamine transmission in brain regions linked to addiction and reward [1,9,10]. This is especially concerning because MPD misuse is exceedingly deadly, with intranasal or intravenous intake having a greater death rate than cocaine and amphetamines [8,11–14]. Furthermore, MPD usage can have negative behavioural effects that result in severe depression, dependence, overdose, and even death [15].Prior to bilateral electrode implantation in the Ventral Tegmental Area (VTA), Locus Coeruleus (LC), Dorsal Raphe (DR), Nucleus Accumbens (NAc), Prefrontal Cortex (PFC), male Sprague Dawley (SD) rats (Harlan Indianapolis, IN, USA) obtained at postnatal day 30-32 were placed individually in the enriched home cage that also served as the test cage in a controlled room with a 12-hour light (CN). All recordings and injections were carried out in the home cages (i.e., the home cage was also employed as the test cage to remove the need for a separate testing cage), and the electrophysiology concurrent with the behavioural recording began at age P-40 for ten consecutive days.novelty of the test cage as a possible treatment confounding factor). The animals were given 30 mg/kg pentobarbital to put them to sleep before having their heads shaved, slathered in lidocaine hydrochloride topical cream, and then set in a stereotactic holder. The skin, muscle, and connective tissue were removed from the head in order to reveal the skull.

The following six brain regions were each given a pair of bilateral holes above them: VTA- posterior (P) from Bregma

6.0 mm and lateral (L) from the midline 0.2 mm, LC- posterior (P) from Bregma 9.3 mm and 1.0 mm, DR- posterior 7.8 mm and 0.2 mm, NAc- anterior (A) from Bregma 1.2 mm, L- 6.0 mm, PFC- anterior 3. The frontal skull's additional holes were bored for the electrodes for comparison.Mallinckrodt provided the hydrochloride form of methylphenidate (MPD) (Hazelwood, MD, USA). The MPD dosages of 0.6 mg/kg, 2.5 mg/kg, and 10.0 mg/kg were determined as a free base after being dissolved in a 0.9% isotonic saline solution. The TBSI and a computerised animal activity monitoring system were used to simultaneously capture the behavioural locomotor activity and the neural activity (Opto-M3, Columbus, OH, USA). A wireless head stage (less than 4.5 grammes in weight) and a remote receiver make up the TBSI system. During 60 minutes during each session, locomotor activity was monitored.Following acute-Experimental Day 1 (ED1) and chronic-Experimental Day 10 (ED10) MPD exposure, each animal's locomotor behaviour was examined using six bins of data, each lasting 10 minutes for a total of 60 minutes. Using the paired t-test,of a rat's lifespan, according to Lee et al. [63] and Yang et al. [62], making them a chronic dose. The CED spike 2.7 programme was used to replay the neural activity that was collected from each electrode offline for statistical analysis and neuronal spike sorting. The computer recorded the neural spikes and processed them using low-pass and high-pass filters (0.3 kHz-3.0 kHz). For spikes demonstrating positive direction and negative direction, respectively, there were two window discrimination levels. We also assess the proportion of the ED10MPD/ED1MPD of neuronal units responding to MPD with increased vs. decreased firing rates among six different brain regions using the 2 test, and the chronic effect of MPD was determined by comparing the ED10MPD/ED1MPD of neuronal units responding to MPD with increased vs. decreased firing rates. Post hoc comparisons are carried out to determine the regions with significantly different ratios of neuronal units reacting to MPD with increased vs. decreased firing rates when compared to other regions, if there are any significant variations between the various brain regions.

Discussion

Alcohol, cocaine, and methamphetamines are just a few of the substances of abuse that have an impact on the mesocorticolimbic catecholaminergic system, which is the neuronal circuit acknowledged as the principal circuit engaged in reinforcement learning [27,44,60,84]. In this system, which consists of the VTA, LC, and DR, DA, NE, and 5HT neurons that are involved in motivation, memory, cognition, and learning also project to the NAc, CN, and PFC. The NAc, particularly the Medium Spiny Neurons (MSNs), which express either D1 or D2 receptors and cause neuronal excitation or inhibition, respectively, are thought to play a significant role in modulating addictive behaviours [22,46,85,86]. Additionally, it has been demonstrated that the PFC modulates and offers inhibitory feedback to the neurons in the NAc and VTA. In the recordings that come after 2.5 mg/kg MPD The neuronal recordings from the behaviorally tolerant animals revealed that the neurons recorded from the PFC, LC, and NAc exhibited the highest responsveness to 2.5 mg/kg MPD, while those obtained from behaviorally sensitised animals showed that the DR neurons were more active than the neurons in the other five brain areas. In conclusion, the data show that MPD has varied effects on each type of brain structure, suggesting that The six distinct brain regions each react to MPD differently. Lower (0.6 mg/kg MPD) and intermediate (2.5 mg/kg MPD) dosages have an impact that alters how the VTA, LC, DR, and NAC respond. Whereas the MPD high dose (10.0 mg/kg MPD) exhibits similar effects on PFC and CN structures influences on each of the six brain structures. As a result, we propose that each of the six brain regions mentioned above plays a unique role in the response to MPD, and that the behavioural manifestation of acute and chronic MPD is the result of push-pull interactions between these brain regions. According to this observation, MPD's calming effect on ADHD patients is caused, at least in part, by its impact on the DR and 5HT system [10], i.e., the serotonergic system plays a substantial role in MPD's effects.

Conclusions

In comparison to the neuronal units recorded from the VTA, LC, NAc, PFC, and CN neurons, the DR neuronal units were most influenced by acute and chronic MPD at doses of 0.6 mg/kg and 2.5 mg/kg. In general, all six brain region units were similarly impacted by 10.0 mg/kg MPD. The amount of neuronal units that responded by speeding up or slowing down their firing rates varied greatly throughout the six brain regions, though.

References

1. Challman TD, Lipsky JJ. Methylphenidate: Its Pharmacology and uses. Mayo Clin Proc. 2000;75(7):711-21.
2. Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;2015(11):CD009885.
3. Safer DJ. Recent trends in stimulant usage. J Atten Disord. 2016;20(6):471-7.
4. Arria AM, Caldeira KM, O'Grady KE, Vincent KB, Johnson EP, Wish ED. Nonmedical use of prescription stimulants

among college students: Associations with attentiondeficit–hyperactivity disorder and Polydrug use. Pharmacotherapy.2008;28(2):156-69.
5. Dietz P, Striegel H, Franke AG, Lieb K, Simon P, Ulrich R. Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy. 2013;33(1):44-50.
6. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature. 2008;456(7223):702-5.
7. Stix G. Turbocharging the brain. Scientific American. 2015.
8. Kim MG, Kim J, Kim SC, Jeong J. Twitter analysis of the nonmedical use and side effects of methylphenidate: Machine Learning Study. J Med Internet Res. 2020;22(2):e16466.
9. Kuczenski R, Segal DS. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci. 2002;22(16):7264-71.
10. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Gifford A, et al. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry. 1999;156(9):1440-3.
11. Garland EJ. Intranasal abuse of prescribed methylphenidate. J Am Acad Child Adolesc Psychiatry. 1998;37(6):573-4.
12. Gatley SJ, Volkow ND, Gifford AN, Fowler JS, Dewey SL, Ding YS, et al. Dopaminetransporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology (Berl). 1999;146(1):93-100.
13. Liana ME, Crismon ML, Crismon ML. Methylphenidate: Increased abuse or appropriate use? J Am Pharm Assoc. 1999;39(4):526-30.
14. Massello W, Carpenter DA. A fatality due to the intranasal abuse of methylphenidate (Ritalin). J Forensic Sci. 1999;44(1):220-1.
15. Morton WA, Stock GG. Methylphenidate abuse and psychiatric side effects. Prim Care Companion J Clin Psychiatry. 2000;2(5):159-64.
16. Broussard E, Reyes-Vazquez C, Dafny N. Methylphenidate dose-response behavioral and neurophysiological study of the ventral tegmental area and nucleus accumbens in adolescent rats. Eur J Neurosci. 2019;50(4):2635-52.
17. Chao J, Nestler EJ. Molecular neurobiology of drug addiction. Ann Rev Med. 2004;55(1):113-32.
18. Dietz DM, Dietz KC, Nestler EJ, Russo SJ. Molecular mechanisms of psychostimulantinduced structural plasticity. Pharmacopsychiatry. 2009;42 Suppl 1(Suppl 1):S69-78.
19. Kim Y, Teylan MA, Baron M, Sands A, Nairn AC, Greengard P. Methylphenidateinduced dendritic spine formation and DeltaFosB expression in nucleus accumbens. Proc Natl Acad Sci U S A. 2009;106(8):2915-20.
20. Nestler EJ. Transcriptional Mechanisms of Drug Addiction. Clinical Psychopharmacol Neurosci. 2012;10(3):136-43.
21. Robison AJ, Nestler EJ. Transcriptional and epigenetic mechanisms of addiction.Nature Rev Neurosci. 2011;12(11):623-37.
22. Venkataraman SS, Claussen CM, Kharas N, Dafny N. The prefrontal cortex and the caudate nucleus respond conjointly to methylphenidate (ritalin). Concomitan behavioral and neuronal recording study. Brain Res Bull. 2020;157:77-89.
23. Bolanos CA, Glatt SJ, Jackson D. Subsensitivity to dopaminergic drugs in periadolescent rats: A behavioral and neurochemical analysis. Developmental Brain Res. 1988;111(1):25-33.
24. Segal DS, Kuczenski R. Behavioral and neurochemical characteristics of stimulantinduced augmentation. Psychopharmacol Bull. 1987;23(3):417-24.
25. Berridge KC, Kringelbach ML. Affective neuroscience of pleasure: Reward in humans and animals. Psychopharmacology (Berl). 2008;199(3):457-80.
26. Haber SN, Knutson B. The reward circuit: Linking Primate anatomy and human imaging. Neuropsychopharmacology. 2010;35(1):4-26.
27. Kalivas PW. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Research. Brain Res Rev. 1993;18(1):75-113.
28. Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci.2013;14(9):609-25.
29. Ikemoto S. Dopamine reward circuitry: Two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev. 2007;56(1):27-78.
30. Kita H, Kitai ST. Amygdaloid projections to the frontal cortex and the striatum in the rat. J Comparative Neurol. 1990;298(1):40-9.
31. Floren S, King N, Carrasco A, Dafny N. Glutamate and dopamine in the VTA participate differently in the acute and chronic effect of methylphenidate. Behav Brain Res. 2020;380:112390.
32. Biederman J, Faraone SV, Mick E, Williamson S, Wilens TE, Spencer TJ, et al. Clinical correlates of ADHD in females: findings from a large group of girls ascertained from © 2022 - Medtext Publications. All Rights Reserved. 020 pediatric and psychiatric referral sources. J Am Acad Child Adolesc Psychiatry. 1999;38(8):966-75.
33. Kuczenski R, Segal DS. Locomotor effects of acute and

repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther. 2001;296(3):876-83.
34. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry. 1996;35(3):264-272.
35. Brun P, Suaud-Chagny MF, Gonon F, Buda M. In vivo noradrenaline release evoked in the anteroventral thalamic nucleus by Locus Coeruleus Activation: An electrochemical study. Neuroscience. 1993;52(4):961-72.
36. Florin-Lechner SM, Druhan JP, Aston-Jones G, Valentino RJ. Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus. Brain Res. 1996;742(1-2):89-97.
37. Amaral D, Sinnamon H. The Locus Coeruleus: Neurobiology of a central noradrenergic nucleus. Prog Neurobiol. 1977;9(3):147-96.
38. Moore RY, Bloom FE. Central catecholamine neuron systems: Anatomy and physiology of the norepinephrine and Epinephrine Systems. Ann Rev Neurosci. 1979;2(1):113-68.
39. Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system:Modulation of Behavioral State and state-dependent cognitive processes. Brain Res Rev. 2003;42(1):33-84.
40. Geyer MA, Warbritton JD, Menkes DB, Zook JA, Mandell AJ. Opposite effects of intraventricular serotonin and bufotenin on rat startle responses. Pharmacol Biochem Behav. 1995;3(4):687-91.
41. Volkow ND, Swanson JM. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Am J Psychiatry. 2008;165(5):553-5.
42. Ranade SP, Mainen ZF. Transient firing of dorsal raphe neurons encodes diverse and specific sensory, motor, and reward events. J Neurophysiol. 2009;102(5):3026-37.
43. Kuczenski R, Segal DS. Dynamic changes in sensitivity occur during the acute response to cocaine and methylphenidate. Psychopharmacology (Berl). 1999;147(1):96-103.
44. Clark L, Cools R, Robbins TW. The neuropsychology of ventral prefrontal cortex: Decision-making and reversal learning. Brain Cogn. 2004;55(1):41-53.
45. Dafny N, Yang PB. The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: A review of its locomotor effects. Brain Res Bull. 2006;68(6):393-405.
46. Claussen CM, Chong SL, Dafny N. Nucleus accumbens neuronal activity correlates to the animal's behavioral response to acute and chronic methylphenidate. Physiol Behav. 2014;129:85-94.
47. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85(14):5274-8.
48. Ming T, Dafny N. Glutaminergic signaling in the nucleus accumbens modulates the behavioral response to acute and chronic methylphenidate. J Exp Neurol. 2021;2(1):49-61.
49. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AFT, Kelley AE, Schmeichel B, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry. 2006;60(10):1111-20.
50. Austin MC, Kalivas PW. Dopaminergic involvement in locomotion elicited from the ventral pallidum/substantia innominata. Brain Res. 1991;542(1):123-31.
51. Wise RA. Addictive drugs and brain stimulation reward. Annu Rev Neurosci.1996;19:319-40.
52. Russell V, Allie S, Wiggins T. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder--the spontaneously hypertensive rat. Behav Brain Res. 2000;117(1-2):69-74.
53. Cadoni C, Solinas M, Di Chiara G. Psychostimulant sensitization: Differential changes in accumbal shell and core dopamine. Eur J Pharmacol. 2000;388(1):69-76.
54. Kalivas PW, Pierce RC, Cornish J, Sorg BA. A role for sensitization in craving and relapse in cocaine addiction. J Psychopharmacol. 1998;12(1):49-53.
55. Podet A, Lee MJ, Swann AC, Dafny N. Nucleus accumbens lesions modulate the effects of methylphenidate. Brain Res Bull. 2010;82(5-6):293-301.
56. Swanson RA, Liu J, Miller JW, Rothstein JD, Farrell K, Stein A, et al. Neuronal regulation of glutamate transporter subtype expression in astrocytes. J Neurosci. 1997;17(3):932-40.
57. Arnsten AFT, Li BM. Neurobiology of executive functions: Catecholamine influences on prefrontal cortical functions. Biol Psychiatry. 2005;57(11):1377-84.
58. Goyal N, Siddiqui SV, Chatterjee U, Kumar D, Siddiqui A. Neuropsychology of prefrontal cortex. Indian J Psychiatry. 2008;50(3):202-8.
59. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev. 1997;25(2):192-216.
60. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: From actions to habits to compulsion. Nat Neurosci. 2005:8(11):1481-9.
61. Rebec GV. Behavioral electrophysiology of psychostimulants.Neuropsychopharmacology. 2006;31(11):2341-8.
62. Yang PB, Swann AC, Dafny N. Sensory-evoked potentials recordings from the ventral tegmental area, nucleus ac-

cumbens, prefrontal cortex, and caudate nucleus and locomotor activity are modulated in dose-response characteristics by methylphenidate. Brain Res. 2006;1073-1074:164-74.
63. Lee SH, Seo WS, Sung HM, Choi TY, Kim SY, Choi S, et al. Effect of methylphenidate on sleep parameters in children with ADHD. Psychiatry Investig. 2012;9(4):384-90.
64. Wanchoo SJ, Lee MJ, Swann AC, Dafny N. Bilateral six-hydroxydopamine administration to PFC prevents the expression of behavioral sensitization to methylphenidate. Brain Res. 2009;1312:89-100.
65. Yang PB, Swann AC, Dafny N. Chronic administration of methylphenidate produces neurophysiological and behavioral sensitization. Brain Res. 2007;1145:66-80.
66. Carr GD, White NM. The relationship between stereotypy and memory improvement produced by Amphetamine. Psychopharmacology (Berl). 1984;82(3):203-9.
67. Claussen CM, Chong SL, Dafny N. Selective bilateral lesion to caudate nucleus modulates the acute and chronic methylphenidate effects. Pharmacol Biochem Behav. 2012;101(2):208-16.
68. Cousins V, Rose JE, Levin ED. IV nicotine self-administration in rats using a consummatory operant licking response: Sensitivity to serotonergic, glutaminergic and histaminergic drugs. Prog Neuropsychopharmacol Biol Psychiatry. 2014;54:200-5.
69. King N, Floren S, Kharas N, Thomas M, Dafny N. Glutaminergic signaling in the caudate nucleus is required for behavioral sensitization to methylphenidate. Pharmacol Biochem Behav. 2019;184:172737.
70. Karim TJ, Reyes-Vazquez C, Dafny N. Comparison of the VTA and LC response to methylphenidate: a concomitant behavioral and neuronal study of adolescent male rats. J Neurophysiol. 2017;118(3):1501-14.
71. Frolov A, Reyes-Vasquez C, Dafny N. Behavioral and neuronal recording of the nucleus accumbens in adolescent rats following acute and repetitive exposure to methylphenidate. J Neurophysiol. 2015;113(1):369-79.
72. Jones Z, Dafny N. Acute and chronic dose-response effect of methylphenidate on ventral tegmental area neurons correlated with animal behavior. J Neural Transm (Vienna). 2014;121(3):327-45.
73. Karim TJ, Aksel C, Kharas N, Reyes-Vasquez C, Dafny N. Caudate nucleus neurons participate in methylphenidate function: Behavioral and neuronal recordings from freely behaving adolescent rats. Brain Res Bull. 2018;142:241-52.
74. Kharas N, Reyes-Vazquez C, Dafny N. Locus coeruleus neuronal activity correlates with behavioral response to acute and chronic doses of methylphenidate (Ritalin) in adolescent rats. J Neural Transm (Vienna). 2017;124(10):1239-50.
75. Venkataraman SS, Joseph M, Dafny N. Concomitant behavioral and prefrontal cortex neuronal responses following acute and chronic methylphenidate exposure in adolescent and adult rats. Brain Res Bull. 2019;144:200-12.
76. Sherwood NM, Timiras P. A stereotaxic atlas of the developing rat brain. Berkeley [u.a.]: University of California Press. 1970.
77. Askenasy EP, Taber KH, Yang PB, Dafny N. Methylphenidate (Ritalin): Behavioral studies in the rat. Int J Neurosci. 2007;117(6):757-94.
78. Gaytan O, Nason R, Alagugurusamy R, Swann A, Dafny N. MK-801 blocks the development of sensitization to the locomotor effects of methylphenidate. Brain Res Bull. 2000;51(6):485-92.
79. Yang PB, Swann AC, Dafny N. Chronic pretreatment with methylphenidate induces cross-sensitization with amphetamine. Life Sci. 2003;73(22):2899-911.
80. Kharas N, Yang P, Castro-Alvarado D, Rose K, Dafny N. Exposure to methylphenidate in adolescence and adulthood modulates cross-sensitization to amphetamine in adulthood in three genetically variant female rat strains. Behav Brain Res. 2019;362:36-45.
81. Tang B, Dafny N. Behavioral and dorsal raphe neuronal activity following acute and chronic methylphenidate in freely behaving rats. Brain Res Bull. 2013;98:53-63.
82. Venkataraman SS, Claussen C, Joseph M, Dafny N. Concomitant behavioral and PFC neuronal activity recorded following dose-response protocol of MPD in adult male rats. Brain Res Bull. 2017;130:125-37.
83. Gaytan O, Ghelani D, Martin S, Swann A, Dafny N. Methylphenidate: Diurnal effects on locomotor and stereotypic behavior in the rat. Brain Res. 1997;777(1-2):1-12.
84. Ikemoto S, Yang C, Tan A. Basal ganglia circuit loops, dopamine and motivation: A review and enquiry. Behav Brain Res. 2015;290:17-31.
85. Claussen CM, Dafny N. Caudate neuronal recording in freely behaving animals following acute and chronic dose response methylphenidate exposure. Pharmacol Biochem Behav. 2015;136:21-30.
86. Claussen CM, Witte LJ, Dafny N. Single exposure of dopamine D1 antagonist prevents and D2 antagonist attenuates methylphenidate effect. J Exp Pharmacol. 2015;7:1-9.
87. Andre P, Carpenter MB. Human Neuroanatomy. Baltimore: The Williams and Wilkens Company; 1976.